Perspectives
AI in Drug Discovery
Over the past 50 years, drug discovery has focused largely on high-throughput screening for known disease-associated targets. This makes drug discovery a long, expensive and largely unsuccessful process.
People
Nishant Sinha
Consulting
Director
Nishant is a Director on Deloitte’s Analytics and Cognitive team. He is a cross-cultural leader with more than 16 years of experience in pharma and financial services. He specialises in machine learning and artificial intelligence. Nishant has worked extensively with organisations across the USA, Canada, UK, Germany and Asia Pacific, helping them build their digital transformation strategy, obtain value from data and build intelligent, data-driven systems of the future.